Hypertension is a common comorbidity in children with CKD1,2 and is associated with progression of CKD in cohort studies and trials.3,4,5 Effective treatment of hypertension is known to slow the rate of progression to end-stage renal disease, as highlighted by the Effect of Strict Blood Pressure Control and Angiotensin-Converting Enzyme Inhibition on the Progression of Chronic Renal Failure in Pediatric Patients (ESCAPE) trial,4 which demonstrated that improved blood pressure (BP) management delayed the progression of CKD, especially among those with proteinuria. Here, ACE is linked to chronic kidney disease.